Clinical trial
Arsucam® (Artesunate + Amiodaquine) Efficacy and TOLerance
NCT00445796 · Sanofi, Industry · Completed
Key facts
| NCT number | NCT00445796 |
|---|---|
| Title | Arsucam® (Artesunate + Amiodaquine) Efficacy and TOLerance |
| Official title | Randomised, Comparative Study of the Efficacy and Safety of Arsucam® Administered as a Single Daily Intake Versus Two Daily Intakes in the Treatment of Plasmodium Falciparum Malaria Attack |
| Acronym | ATOL |
| Lead sponsor | Sanofi, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Malaria |
| Intervention type | Drug |
| Interventions | Artesunate, Amodiaquine |
| Enrollment | 300 |
| Start date | Jun 1, 2005 |
| First posted | Mar 9, 2007 |
| Last update posted | Apr 10, 2008 |
| Countries | Cameroon, Senegal |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: